Focus Brief: Market Access Weekly September 1 to 7, 2025
Global market access shifts: HTA speed, UK pricing, digital disruption.
By subject
NCPE Recommends Conditional Access for Omeprazole
NCPE recommends Omeprazole Appizped for reimbursement eligibility.
NCPE Recommends Vabysmo, Signaling Retinal Policy Shift
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
New Reimbursement Strategy Boosts Ambulatory Pay
New partnership advances reimbursement strategy for private practices.
South Korea’s Drug Pricing Reforms Reshape Market Access Landscape
South Korea’s new pharma pricing reforms reward innovation and expand access for industry.
NICE Expands TAVI Guidance for Aortic Valve Regurgitation
Quick Summary: NICE has published new interventional procedures guidance recommending the use of transcatheter aortic valve implantation (TAVI) for patients with native aortic valve regurgitation. This guidance enables wider access to TAVI as a less invasive alternative to open-heart surgery for eligible NHS patients, with a key focus on multidisciplinary team-based patient selection and … Read more
NICE Guidance Catalyzes Digital Mental Health Innovation
NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.
Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
GoodRx Disrupts Pharmacy Economics with Cost-Plus Pricing
GoodRx reshapes independent pharmacy economics through transparent cost-plus pricing model launch.